home / stock / prnb / prnb news

PRNB News and Press, Principia Biopharma Inc. From 10/15/19

Stock Information
Company Name: Principia Biopharma Inc.
Stock Symbol: PRNB
Market: NASDAQ
Website: principiabio.com
Menu
PRNB PRNB Quote PRNB Short PRNB News PRNB Articles PRNB Message Board
Get PRNB Alerts

News, Short Squeeze, Breakout and More Instantly...
PRNB - Principia Announces Positive Preliminary Data of PRN1008 for Immune Thrombocytopenia in Ongoing Phase 1/2 Trial

SOUTH SAN FRANCISCO, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated diseases, today announced positive preliminary data from an ongoing Phase 1/2 trial of its investi...
PRNB - Principia's lead candidate shows positive action in second stage of pemphigus study

Principia Biopharma (NASDAQ: PRNB ) announces positive preliminary data from Part B of its open-label Phase 2 clinical trial evaluating lead candidate PRN1008 in pemphigus patients. More news on: Principia Biopharma Inc., Healthcare stocks news, Stocks on the move, Read more ...

PRNB - Principia Announces Positive Preliminary Data of PRN1008 from its Ongoing Phase 2 Part B Trial in Pemphigus

Consistent efficacy and safety profile for pemphigus patients observed  Confirms 400mg twice daily dose in Phase 3 trial Principia to host investor conference call at 8:00 am Eastern time SOUTH SAN FRANCISCO, Calif., Oct. 10, 2019 (GLOBE NEWSWIRE) --  Principia Bioph...

PRNB - Principia Biopharma Appoints Shawn Tomasello to Its Board of Directors

SOUTH SAN FRANCISCO, Calif., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced t...
PRNB - Principia to Present at the 2019 Baird Global Healthcare Conference and the Wells Fargo Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced t...

PRNB - Principia Biopharma EPS of $0.28

Principia Biopharma (NASDAQ: PRNB ): Q2 EPS of $0.28 may not be comparable to consensus of -$0.65. More news on: Principia Biopharma Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

PRNB - Principia Biopharma Reports Second Quarter Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced fin...
PRNB - Principia Announces Update to Ongoing Phase 2 Clinical Trial in Patients with ITP

SOUTH SAN FRANCISCO, Calif., July 30, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced upd...

PRNB - Credit Suisse sees 23% upside in United Therapeutics in today's analyst action

IsoRay ( ISR +3.2% ) initiated with Buy rating and $1 (138% upside) price target at Dawson James. More news on: IsoRay, Inc., United Therapeutics Corporation, Dr. Reddy's Laboratories Limited, Healthcare stocks news, Stocks on the move, , Read more ...

PRNB - Credit Suisse sees 23% upside in United Therapeutics in today's analyst action

IsoRay ( ISR +3.2% ) initiated with Buy rating and $1 (138% upside) price target at Dawson James. More news on: IsoRay, Inc., United Therapeutics Corporation, Dr. Reddy's Laboratories Limited, Healthcare stocks news, Stocks on the move, , Read more ...

Previous 10 Next 10